Literature DB >> 22534508

Curing bacteria of antibiotic resistance: reverse antibiotics, a novel class of antibiotics in nature.

Keiichi Hiramatsu1, Masayuki Igarashi, Yuh Morimoto, Tadashi Baba, Maya Umekita, Yuzuru Akamatsu.   

Abstract

By screening cultures of soil bacteria, we re-discovered an old antibiotic (nybomycin) as an antibiotic with a novel feature. Nybomycin is active against quinolone-resistant Staphylococcus aureus strains with mutated gyrA genes but not against those with intact gyrA genes against which quinolone antibiotics are effective. Nybomycin-resistant mutant strains were generated from a quinolone-resistant, nybomycin-susceptible, vancomycin-intermediate S. aureus (VISA) strain Mu 50. The mutants, occurring at an extremely low rate (<1 × 10(-11)/generation), were found to have their gyrA genes back-mutated and to have lost quinolone resistance. Here we describe nybomycin as the first member of a novel class of antibiotics designated 'reverse antibiotics'.
Copyright © 2012 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22534508     DOI: 10.1016/j.ijantimicag.2012.02.007

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  22 in total

1.  Genetic and Transcriptomic Analyses of Ciprofloxacin-Tolerant Staphylococcus aureus Isolated by the Replica Plating Tolerance Isolation System (REPTIS).

Authors:  Miki Matsuo; Miyu Hiramatsu; Madhuri Singh; Takashi Sasaki; Tomomi Hishinuma; Norio Yamamoto; Yuh Morimoto; Teruo Kirikae; Keiichi Hiramatsu
Journal:  Antimicrob Agents Chemother       Date:  2019-01-29       Impact factor: 5.191

2.  Comprehensive identification of mutations responsible for heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA)-to-VISA conversion in laboratory-generated VISA strains derived from hVISA clinical strain Mu3.

Authors:  Miki Matsuo; Longzhu Cui; Jeeyoung Kim; Keiichi Hiramatsu
Journal:  Antimicrob Agents Chemother       Date:  2013-09-09       Impact factor: 5.191

3.  Diazaquinomycin Biosynthetic Gene Clusters from Marine and Freshwater Actinomycetes.

Authors:  Jana Braesel; Jung-Ho Lee; Benoit Arnould; Brian T Murphy; Alessandra S Eustáquio
Journal:  J Nat Prod       Date:  2019-03-21       Impact factor: 4.050

4.  Synthetic studies on the reverse antibiotic natural products, the nybomycins.

Authors:  Oliver A Bardell-Cox; Andrew J P White; Luis Aragón; Matthew J Fuchter
Journal:  Medchemcomm       Date:  2019-05-24       Impact factor: 3.597

5.  Endless Resistance. Endless Antibiotics?

Authors:  Jed F Fisher; Shahriar Mobashery
Journal:  Medchemcomm       Date:  2015-11-03       Impact factor: 3.597

Review 6.  Instructive Advances in Chemical Microbiology Inspired by Nature's Diverse Inventory of Molecules.

Authors:  Ke Liu; Robert W Huigens
Journal:  ACS Infect Dis       Date:  2020-01-06       Impact factor: 5.084

7.  Predictive compound accumulation rules yield a broad-spectrum antibiotic.

Authors:  Michelle F Richter; Bryon S Drown; Andrew P Riley; Alfredo Garcia; Tomohiro Shirai; Riley L Svec; Paul J Hergenrother
Journal:  Nature       Date:  2017-05-10       Impact factor: 49.962

Review 8.  The challenge of converting Gram-positive-only compounds into broad-spectrum antibiotics.

Authors:  Michelle F Richter; Paul J Hergenrother
Journal:  Ann N Y Acad Sci       Date:  2018-02-15       Impact factor: 5.691

Review 9.  Facilitating Compound Entry as a Means to Discover Antibiotics for Gram-Negative Bacteria.

Authors:  Kristen A Muñoz; Paul J Hergenrother
Journal:  Acc Chem Res       Date:  2021-02-26       Impact factor: 22.384

10.  Structure Determination, Functional Characterization, and Biosynthetic Implications of Nybomycin Metabolites from a Mining Reclamation Site-Associated Streptomyces.

Authors:  Xiachang Wang; Sherif I Elshahawi; Larissa V Ponomareva; Qing Ye; Yang Liu; Gregory C Copley; James C Hower; Bruce E Hatcher; Madan K Kharel; Steven G Van Lanen; Qing-Bai She; S Randal Voss; Jon S Thorson; Khaled A Shaaban
Journal:  J Nat Prod       Date:  2019-12-13       Impact factor: 4.050

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.